ReviewCurrent treatment options in oncology2022
Advances in Organ Preservation for Laryngeal Cancer.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Survival outcomes of the patients with advanced laryngeal squamous cell carcinoma treated with chemoradiotherapy and total laryngectomy based on reports of head and neck cancer registry of Japan.International journal of clinical oncology · 2026Article
- Adjuvant radiotherapy in pT3 glottic squamous cell carcinoma: an unnecessary burden?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- IL-23 as a potential mediator of immune evasion and therapeutic target in laryngeal squamous cell carcinoma.BMC cancer · 2026Article
- Anticancer Effects of Galium aparine L Extract: Dose-Dependent Cytotoxicity in HNO210 Human Laryngeal Carcinoma Cells.The Journal of craniofacial surgery · 2026Article
- Role of microRNA-761 in modulating laryngeal cancer cell proliferation, metastasis, and apoptosis: regulation of PDCD4 as a key mechanism.Molecular biology reports · 2025Article
- Targeting TNFAIP2 with NIR-II CRISPR-Cas9 nanosystem to overcome cisplatin resistance in laryngeal cancer.NPJ precision oncology · 2025Article
- Laryngeal Cancer in the Modern Era: Evolving Trends in Diagnosis, Treatment, and Survival Outcomes.Journal of clinical medicine · 2025Review
- Supracricoid partial laryngectomy and reconstruction of the anterior epiglottic space flap: a new surgical approach for supracricoid partial laryngectomy.Frontiers in oncology · 2025Article
- Influential Factors on Survival in Laryngeal Cancer and Treatment Modalities Comparison.ORL; journal for oto-rhino-laryngology and its related specialties · 2025Article
- Challenges in chemotherapy for head and neck cancer: A review.Bioinformation · 2025Article
- Psychological Well-Being and Quality of Life in Laryngeal Cancer Patients across Tumor.Journal of clinical medicine · 2024Article
- Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Diseases (Basel, Switzerland) · 2024Article
- Individualized treatment recommendations for patients with locally advanced head and neck squamous cell carcinoma utilizing deep learning.Frontiers in medicine · 2024Article
- Survival in an era of organ preservation: an update on laryngeal cancer in Ireland.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- COAmerican journal of translational research · 2023Article
- Oncological Analysis and Surgical Outcomes in Postcricoid Carcinoma: A 14 Years Retrospective Study.Cancers · 2022Article
- Laryngeal Preservation Rate and Salvage Therapy Following Initial Recurrence in a Real-world Setting After Definitive Radiation Therapy in Patients With Locally Advanced Laryngeal Squamous Cell Carcinoma.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
opinion statementAt the University of Wisconsin, all treatment of head and neck cancer patients begins with discussion at our multi-disciplinary tumor board. Most patients with T4 disease, with existing laryngeal dysfunction, considered unlikely to complete definitive CRT or who have a high risk of persistent aspiration after non-operative management undergo total laryngectomy. A laryngeal sparing approach is attempted on most other patients. Radiotherapy is delivered over 6.5 weeks, preferably with concurrent weekly cisplatin. If the patient is hesitant of chemotherapy or has contraindications to cisplatin, concurrent cetuximab may be offered. Patients treated with RT alone are often treated to the same dose, but via an accelerated schedule by adding a 6th fraction per week. The 6th fraction is given by delivering two treatments at least 6 h apart on a weekday of the patient's choosing. We consider the following to be major risk factors for clinically significant weight loss during treatment: a 10% or greater loss of weight in the 6 months prior to starting treatment, delivery of concurrent cisplatin, and treatment of the bilateral neck with radiation. Patients who have 2-3 of these characteristics are often given gastrostomy tubes prophylactically. Patients are seen 2 weeks after completion of therapy, and then every 3 months after completion for 2 years. A CT neck and PET-CT are performed at the first 3-month visit. They are seen twice in year three, and then yearly until years 5-7. At each of these visits, we have a low threshold to present the patient at our multidisciplinary tumor board for consideration of salvage laryngectomy if there are signs of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.